UNITED THERAPEUTICS CORP (UTHR.MX)

Compare

6,902.22

0.00

(0.00%)

At close: October 9 at 9:10:50 AM CST

Drugmakers Show Restraint on Price Increases in New Trump Era

Drugmakers raised the list prices of more than 800 prescription drugs for blood pressure, cancer and other conditions by a median 4% at the start of this year. The modest size of the annual increases could help companies avoid criticism of gouging from President Trump while seeking his administration’s support for such priorities as taking aim at the rebates given to middlemen and altering a federal program providing discounts to certain hospitals. Last year’s median price increase was 4.5%.

The Wall Street Journal 3 days ago

PFE

AMGN

UTHR
United Therapeutics Corporation to Feature Clinical Data Across its Commercial and Development Portfolio at the Pulmonary Vascular Research Institute 2025 Annual Congress

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., January 21, 2025--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that five posters across its commercial and development portfolio in pulmonary hypertension (PH) will be presented at the Pulmonary Vascular Research Institute (PVRI) 2025 Annual Congress taking place January 29 through February 1, 2025 in Rio de Janeiro. In addition, professionals from United Therapeutics will participate in two speak

Business Wire 11 days ago

UTHR
United Therapeutics Corporation to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., January 06, 2025--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Dr. Martine Rothblatt, Chairperson and Chief Executive Officer, will provide an overview and update on the company’s business during a presentation at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco.

Business Wire 26 days ago

UTHR
We Ran A Stock Scan For Earnings Growth And United Therapeutics (NASDAQ:UTHR) Passed With Ease

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

Simply Wall St. last month

UTHR
United Therapeutics Announces Successful World’s First UKidney Transplant

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., December 17, 2024--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the world’s first transplant of a UKidney, which it produced, into a living person on November 25, 2024.

Business Wire last month

UTHR
The 3.8% return this week takes United Therapeutics' (NASDAQ:UTHR) shareholders five-year gains to 314%

We think all investors should try to buy and hold high quality multi-year winners. While the best companies are hard to...

Simply Wall St. 2 months ago

UTHR
United Therapeutics Corporation to Present at the UBS Global Healthcare Conference

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., November 05, 2024--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Patrick Poisson, Executive Vice President, Technical Operations, will provide an overview and update on the company’s operations during a fireside chat session at the UBS Global Healthcare Conference in Rancho Palos Verdes, CA.

Business Wire 2 months ago

UTHR
United Therapeutics Corporation Reports Third Quarter 2024 Financial Results

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., October 30, 2024--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended September 30, 2024. Total revenues in the third quarter of 2024 grew 23 percent year-over-year to $748.9 million, compared to $609.4 million in the third quarter of 2023.

Business Wire 3 months ago

UTHR
United Therapeutics Corporation Announces the 500th Lung Transplant Utilizing its Centralized Ex Vivo Lung Perfusion Service

SILVER SPRING, Md. & JACKSONVILLE, Fla., October 23, 2024--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, and its subsidiary Lung Bioengineering Inc. (LBE) announced that the 500th lung transplant utilizing LBE’s centralized ex vivo lung perfusion (EVLP) service was completed last month. These 500 transplants were the result of evaluating over 800 donated lungs using centralized EVLP since 2014.

Business Wire 3 months ago

UTHR
United Therapeutics Corporation to Report Third Quarter 2024 Financial Results Before the Market Opens on Wednesday, October 30, 2024

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., October 23, 2024--United Therapeutics Corporation (Nasdaq: UTHR), announced today that it will report its third quarter 2024 financial results before the market opens on Wednesday, October 30, 2024. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time.

Business Wire 3 months ago

UTHR
Profitable Biotech In Buy Zone As Earnings Approach

This biotech stock hit a buy point and a new high. The company's sales and earnings continue to grow with earnings out soon.

Investor's Business Daily 3 months ago

UTHR
United Therapeutics Corporation to Present at the Leerink Partners Global Biopharma Conference 2024

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., March 05, 2024--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Patrick Poisson, Executive Vice President, Technical Operations, will provide an overview and update on the company’s operations during a fireside chat session at the Leerink Partners Global Biopharma Conference 2024 in Miami Beach, Florida.

Business Wire 10 months ago

UTHR
United Therapeutics Corporation to Present at the TD Cowen 44th Annual Health Care Conference

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., February 27, 2024--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Michael Benkowitz, President and Chief Operating Officer, will provide an overview and update on the company’s operations during a fireside chat session at the TD Cowen 44th Annual Health Care Conference in Boston.

Business Wire 10 months ago

UTHR
United Therapeutics Corporation Reports Fourth Quarter and Full Year 2023 Financial Results

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., February 21, 2024--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter and year ended December 31, 2023. Full year 2023 revenues rose to a record $2.33 billion, reflecting 20% growth over 2022.

Business Wire 11 months ago

UTHR
United Therapeutics Commences Litigation to Ensure Fairness in the Drug Review Process

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., February 21, 2024--United Therapeutics Corporation (Nasdaq: UTHR) announced today the commencement of litigation with the United States Food and Drug Administration (FDA). In the litigation, United Therapeutics alleges that the FDA mistakenly permitted Liquidia Corporation (Liquidia) to skirt longstanding FDA rules, precedents, and procedures on how pending drug approval applications are handled by the agency. In doing so, the FDA inappropriatel

Business Wire 11 months ago

UTHR

Performance Overview

Return	UTHR.MX	MSCI WORLD
YTD	0.00%	+3.16%
1-Year	0.00%	+19.69%
3-Year	0.00%	+25.42%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

UNITED THERAPEUTICS CORP (UTHR.MX)

Drugmakers Show Restraint on Price Increases in New Trump Era

United Therapeutics Corporation to Feature Clinical Data Across its Commercial and Development Portfolio at the Pulmonary Vascular Research Institute 2025 Annual Congress

United Therapeutics Corporation to Present at the 43rd Annual J.P. Morgan Healthcare Conference

We Ran A Stock Scan For Earnings Growth And United Therapeutics (NASDAQ:UTHR) Passed With Ease

United Therapeutics Announces Successful World’s First UKidney Transplant

The 3.8% return this week takes United Therapeutics' (NASDAQ:UTHR) shareholders five-year gains to 314%

United Therapeutics Corporation to Present at the UBS Global Healthcare Conference

United Therapeutics Corporation Reports Third Quarter 2024 Financial Results

United Therapeutics Corporation Announces the 500th Lung Transplant Utilizing its Centralized Ex Vivo Lung Perfusion Service

United Therapeutics Corporation to Report Third Quarter 2024 Financial Results Before the Market Opens on Wednesday, October 30, 2024

Profitable Biotech In Buy Zone As Earnings Approach

United Therapeutics Corporation to Present at the Leerink Partners Global Biopharma Conference 2024

United Therapeutics Corporation to Present at the TD Cowen 44th Annual Health Care Conference

United Therapeutics Corporation Reports Fourth Quarter and Full Year 2023 Financial Results

United Therapeutics Commences Litigation to Ensure Fairness in the Drug Review Process

Performance Overview